Share This Page
Drug Price Trends for ARIPIPRAZOLE
✉ Email this page to a colleague
Average Pharmacy Cost for ARIPIPRAZOLE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ARIPIPRAZOLE 15 MG TABLET | 82009-0091-05 | 0.13167 | EACH | 2026-03-18 |
| ARIPIPRAZOLE 10 MG TABLET | 82009-0090-05 | 0.10313 | EACH | 2026-03-18 |
| ARIPIPRAZOLE 5 MG TABLET | 82009-0089-05 | 0.09769 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for ARIPIPRAZOLE
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| ARIPIPRAZOLE 15MG TAB | Golden State Medical Supply, Inc. | 60505-2675-03 | 30 | 42.60 | 1.42000 | EACH | 2023-06-16 - 2028-06-14 | FSS |
| ARIPIPRAZOLE 20MG TAB | Golden State Medical Supply, Inc. | 60505-2676-03 | 30 | 48.99 | 1.63300 | EACH | 2023-06-16 - 2028-06-14 | FSS |
| ARIPIPRAZOLE 30MG TAB | Golden State Medical Supply, Inc. | 60505-2677-03 | 30 | 48.99 | 1.63300 | EACH | 2023-06-16 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Aripiprazole Market Dynamics and Price Forecast
Aripiprazole, marketed primarily as Abilify, is a blockbuster antipsychotic drug. Its market trajectory is shaped by patent expirations, generic competition, and evolving treatment paradigms for schizophrenia, bipolar disorder, and depression. The global market for aripiprazole is projected to experience a compound annual growth rate (CAGR) of approximately 3% from 2023 to 2028, reaching an estimated $7.5 billion by 2028.
What are the Key Therapeutic Areas for Aripiprazole?
Aripiprazole is primarily indicated for the treatment of the following conditions:
- Schizophrenia: A chronic and severe mental disorder that affects how a person thinks, feels, and behaves.
- Bipolar I Disorder: Characterized by distinct periods of elevated or irritable mood (mania) and depression.
- Major Depressive Disorder (MDD): A mood disorder characterized by persistent sadness and loss of interest. Aripiprazole is approved as an adjunctive treatment for MDD.
- Irritability Associated with Autistic Disorder: Used to manage irritability in children and adolescents with autism.
- Tourette's Disorder: Approved for the treatment of motor and vocal tics in children and adolescents.
What is the Patent Landscape for Aripiprazole?
The original patents for aripiprazole, held by Otsuka Pharmaceutical, have largely expired in major markets, significantly impacting market dynamics.
- United States: The primary U.S. patent for aripiprazole expired in 2015. Subsequent patents related to specific formulations and methods of use also expired, paving the way for generic entry.
- Europe: Similar to the U.S., key patents in Europe expired in the mid-2010s. The Supplementary Protection Certificates (SPCs) also expired, allowing for generic competition.
- Japan: Japanese patent expiry also occurred around 2015, leading to the availability of generic versions.
The expiration of these foundational patents has resulted in widespread generic availability, leading to a significant decrease in the average selling price (ASP) of aripiprazole.
How Has Generic Competition Impacted Aripiprazole Pricing?
The introduction of generic aripiprazole has been the primary driver of price erosion.
- Price Reduction: Following the entry of generic manufacturers, the ASP for aripiprazole has fallen by an estimated 70-85% in developed markets compared to its branded peak. For instance, the average wholesale price (AWP) of a 30-day supply of Abilify (brand-name) in 2014 was approximately $400-$500. By 2020, generic aripiprazole was available for as low as $30-$60 for the same supply.
- Market Share Shift: Generic versions now command over 90% of the aripiprazole market volume in the U.S. and Europe. This shift is a direct consequence of lower costs for healthcare providers, pharmacies, and ultimately, patients and insurers.
- Competition Dynamics: Multiple generic manufacturers compete in the market, further intensifying price pressure. Key generic players include Teva Pharmaceutical Industries, Mylan (now Viatris), Sun Pharmaceutical Industries, and Accord Healthcare.
What are the Key Market Segments and Their Growth Prospects?
The aripiprazole market can be segmented by formulation, indication, and distribution channel.
By Formulation
- Oral Tablets: This is the dominant formulation, accounting for over 80% of the market share. Its widespread adoption is due to ease of administration and cost-effectiveness.
- Oral Solution: A smaller but significant segment, particularly for pediatric patients or those with difficulty swallowing tablets.
- Long-Acting Injectables (LAI): Formulations such as Abilify Maintena and Aristada represent a premium segment.
- Abilify Maintena: A once-monthly intramuscular injection. Its market share is growing due to improved patient adherence and potentially better symptom control for some individuals. The market for LAI aripiprazole is projected to grow at a CAGR of approximately 6-8% from 2023-2028.
- Aristada: Offers extended-release options, including a 6-week dosing interval, further enhancing convenience and adherence.
By Indication
- Schizophrenia: Remains the largest indication, driving significant volume.
- Bipolar Disorder: A substantial contributor to market demand.
- Major Depressive Disorder (Adjunctive): Growing use as an add-on therapy, particularly for treatment-resistant depression.
- Other Indications (Autism, Tourette's): These represent smaller but stable market segments.
By Distribution Channel
- Hospital Pharmacies: Significant volume for inpatient treatment of acute psychiatric episodes.
- Retail Pharmacies: The largest channel for outpatient prescription fulfillment.
- Online Pharmacies: An increasing channel, particularly for lower-cost generic options.
What are the Projected Market Trends and Price Forecasts?
The aripiprazole market is expected to continue its moderate growth trajectory, driven by its established efficacy and the expansion of long-acting injectable formulations.
- Overall Market Growth: The global aripiprazole market is projected to grow from an estimated $6.0 billion in 2023 to $7.5 billion by 2028, a CAGR of approximately 3%. This growth is primarily fueled by the increasing adoption of LAI formulations and continued demand in emerging markets.
- Generic Tablet Pricing: The ASP for generic oral aripiprazole tablets is expected to remain stable or decline slightly, likely ranging between $15-$40 per month's supply, depending on the country, pharmacy, and insurance coverage. Price competition among generic manufacturers will continue to be fierce.
- LAI Formulation Pricing: Long-acting injectable aripiprazole formulations will command premium pricing.
- Abilify Maintena (once-monthly LAI): The ASP is projected to be in the range of $800-$1,200 per dose (monthly), leading to an annual cost of $9,600-$14,400.
- Aristada (extended-release LAI): Pricing for Aristada will vary based on the dosing interval (e.g., 4-week, 6-week, 8-week). The annual cost for Aristada could range from $10,000 to $18,000 per patient.
- Emerging Market Penetration: Growth in emerging markets in Asia-Pacific and Latin America will contribute to overall market expansion as access to essential medicines improves and healthcare infrastructure develops. Generic aripiprazole is crucial in these regions due to its affordability.
- Market Restraint: The availability of newer antipsychotic agents with potentially improved side-effect profiles or novel mechanisms of action may present a long-term competitive challenge, though aripiprazole's established safety and efficacy profile ensures continued relevance.
What Factors Influence Aripiprazole Demand?
Several factors influence the demand for aripiprazole:
- Prevalence of Mental Health Disorders: The increasing global prevalence of schizophrenia, bipolar disorder, and depression directly drives demand.
- Treatment Guidelines and Physician Prescribing Habits: Adoption of aripiprazole in clinical guidelines and physician familiarity with its use are key drivers.
- Patient Adherence: Long-acting injectables offer an advantage in improving patient adherence compared to daily oral medications, influencing the choice of formulation.
- Healthcare Reimbursement Policies: Insurance coverage and reimbursement levels significantly impact patient access and physician prescribing decisions, particularly for higher-cost LAI formulations.
- Generic Availability and Affordability: The widespread availability of affordable generic oral tablets ensures broad access, especially in cost-sensitive markets.
What are the Regulatory Considerations?
Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) oversee the approval and marketing of aripiprazole.
- Generic Approvals: Regulatory agencies have approved numerous generic versions of aripiprazole, ensuring bioequivalence to the innovator product.
- Labeling and Post-Marketing Surveillance: Ongoing pharmacovigilance monitors safety and efficacy, and label updates may occur based on new findings.
- Biosimilar vs. Generic: Aripiprazole is a small molecule drug, so the relevant term is "generic," not "biosimilar."
What are the Key Competitive Threats and Opportunities?
The competitive landscape for aripiprazole is multifaceted.
Threats
- Newer Antipsychotic Agents: Development of novel drugs with superior efficacy or safety profiles.
- Interchangeable Biosimil Products: While not directly applicable to aripiprazole, this concept highlights potential future competition in other drug classes.
- Pricing Pressures: Continued downward pressure on generic prices.
- Off-Label Use Restrictions: Potential limitations on off-label prescribing.
Opportunities
- Growth in Long-Acting Injectables: Expansion of the LAI market segment driven by improved patient outcomes and adherence.
- Emerging Markets: Untapped potential in developing countries with growing healthcare expenditure.
- Combination Therapies: Investigating aripiprazole in novel combination therapies for complex psychiatric conditions.
- Life-Cycle Management: Development of new formulations or delivery systems for aripiprazole.
Key Takeaways
- The aripiprazole market is mature, dominated by generic oral formulations with significant price erosion since patent expiry.
- Long-acting injectable (LAI) formulations represent a high-growth segment due to improved patient adherence and premium pricing.
- Global market growth is projected at approximately 3% CAGR from 2023-2028, driven by LAIs and emerging market penetration.
- Generic oral aripiprazole prices are expected to remain low ($15-$40/month), while LAI prices will range from $9,600-$18,000 annually per patient.
- The prevalence of mental health disorders and healthcare reimbursement policies are primary demand drivers.
Frequently Asked Questions
-
What is the primary reason for the significant price drop in aripiprazole over the past decade? The primary reason is the expiration of key patents for the original branded product (Abilify), which allowed numerous generic manufacturers to enter the market. This increased competition led to a substantial decrease in the average selling price.
-
Will the price of generic aripiprazole tablets continue to decline? While prices may see minor fluctuations due to intense competition and supply chain factors, significant further declines from current levels are unlikely. The market has largely stabilized around a low price point for generics.
-
What is the market outlook for long-acting injectable (LAI) aripiprazole formulations? The LAI segment is projected for robust growth, driven by patient preference for improved adherence and the clinical benefits observed in certain patient populations. These formulations will maintain premium pricing.
-
Are there any new patent filings or upcoming patent cliffs for aripiprazole that could impact its market in the near future? The foundational patents have expired. While secondary patents for specific formulations or manufacturing processes may exist, they are unlikely to create significant disruptions comparable to the initial patent cliff. The focus has shifted to lifecycle management for existing LAI products.
-
How does the demand for aripiprazole in emerging markets compare to developed markets? Emerging markets represent a significant growth opportunity. While volumes are increasing, the demand is primarily for the affordable generic oral formulations. Penetration of more expensive LAI formulations in these markets is currently limited but is expected to grow as healthcare infrastructure and reimbursement capabilities improve.
Citations
[1] Global Market Insights. (2023). Antipsychotic Drugs Market Share, Size, Trends Analysis Report.
[2] Grand View Research. (2023). Aripiprazole Market Size, Share & Trends Analysis Report.
[3] IQVIA Market Insights. (2023). Global Pharmaceutical Market Trends and Forecasts. (Data pertains to generic drug pricing trends and market penetration).
[4] Various Pharmaceutical Company Investor Reports and Public Filings (e.g., Otsuka Pharmaceutical, Teva Pharmaceutical Industries, Lundbeck) detailing drug sales, patent expiry dates, and market performance. (General reference for patent expiry and generic landscape).
[5] U.S. Food and Drug Administration (FDA) Orange Book Database. (Accessed 2023). Approved Drug Products with Therapeutic Equivalence Evaluations. (Data on approved generic aripiprazole products).
More… ↓
